The financing represents another important milestone and underlines the company's ability to achieve sustainable growth. Cansativa is one of the very few companies in the still young medical cannabis industry that is generating profits and has been able to secure excellent credit terms.
"Our sustainable growth over the last three years, as well as our future-proof business model, makes this debt financing possible and drives our development from a young start-up to a traditional SME,” says Benedikt Sons, CEO and Co-Founder of Cansativa GmbH.
The company will use the funds received from the loan financing for working capital to increase its inventory and to make investments in tangible fixed assets at its second facility in Mörfelden-Walldorf.
"This financing unlocks the company’s full potential and accelerates our further growth by adding new products to our unique multi-brand portfolio over the next months,” adds Jakob Sons, General Counsel and Co-Founder of Cansativa GmbH.
Cansativa plays a dominating role in the German market that is the largest and by far fastest growing medical cannabis market in Europe. The financing thus helps Cansativa to further establish itself as the single point of contact for pharmacies for all aspects of the special range of medical cannabis and to ensure the supply of medical cannabis in the German market with its "one-stop shop".
In addition to the successful loan financing, Cansativa is currently raising further growth capital in a Series A, which will be closed this summer.
About Cansativa GmbH
Founded in 2017, Cansativa is a GMP-certified pharmaceutical company and holds a GDP pharmaceutical wholesale license to trade in controlled substances. From its headquarter in Moerfelden-Walldorf, Germany, Cansativa and its subsidiaries work to professionalize the medical cannabis market, eliminate stigmatization and to permanently reduce prices for patients. As an owner-managed company, our growth target is linked to a long-term vision - we want to set industry-wide benchmarks.
Since the very beginning, Cansativa has operated its own distribution and fulfillment center, and as one of its industry’s “first movers”, it has become one of the largest independent manufacturers, importers, and distributors of medical cannabis in Germany. From its location in Mörfelden-Walldorf, the company supplies pharmacies and pharmaceutical wholesalers throughout Germany. Cansativa is uniquely positioned as „one-stop shop“ with a comprehensive multi-brand portfolio in the German market and secures the supply of medical cannabis pharmaceuticals. Through our top-notch partnership network with well-known supplier, pharmacists can order a broad range of products such as API, pharmaceuticals and medical devices via our Cansativa platform. [PDF]
Investor Relations Cansativa GmbH